Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INGN Stock Forecast 2026-2027
$6.50
Current Price
$168.86M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INGN Price Targets
+115.4%
To High Target of $14.00
+100.0%
To Median Target of $13.00
+84.6%
To Low Target of $12.00
INGN Price Momentum
-10.0%
1 Week Change
-4.8%
1 Month Change
-40.3%
1 Year Change
-3.3%
Year-to-Date Change
-49.7%
From 52W High of $12.91
+14.0%
From 52W Low of $5.70
📊 TOP ANALYST CALLS
Did INGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inogen is one of their latest high-conviction picks.
Latest INGN Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, INGN has a bullish consensus with a median price target of $13.00 (ranging from $12.00 to $14.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $6.50, the median forecast implies a 100.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Anderson Schock at B. Riley Securities, projecting a 115.4% upside. Conversely, the most conservative target is provided by Mike Matson at Needham, suggesting a 84.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INGN Analyst Ratings
2
Buy
0
Hold
0
Sell
INGN Price Target Range
Low
$12.00
Average
$13.00
High
$14.00
Current: $6.50
Latest INGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 16, 2025 | B. Riley Securities | Anderson Schock | Buy | Initiates | $14.00 |
| May 22, 2025 | Needham | Mike Matson | Buy | Upgrade | $12.00 |
| May 8, 2025 | Stifel | Mathew Blackman | Hold | Maintains | $7.00 |
| Apr 9, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Feb 27, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Feb 26, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Jan 30, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Jan 14, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Nov 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Aug 7, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| May 8, 2024 | Stifel | Mathew Blackman | Hold | Maintains | $7.00 |
| May 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Apr 9, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Feb 15, 2024 | William Blair | Margaret Kaczor | Outperform | Upgrade | $N/A |
| Nov 8, 2023 | JP Morgan | Robbie Marcus | Underweight | Maintains | $7.00 |
| Aug 8, 2023 | JP Morgan | Robbie Marcus | Underweight | Downgrade | $8.00 |
| Aug 8, 2023 | Stifel | Mathew Blackman | Hold | Maintains | $8.00 |
| Jul 14, 2023 | Needham | Mike Matson | Hold | Downgrade | $N/A |
| Apr 20, 2023 | Needham | Mike Matson | Buy | Reiterates | $26.00 |
| Feb 28, 2023 | Needham | Mike Matson | Buy | Reiterates | $26.00 |
Inogen Inc. (INGN) Competitors
The following stocks are similar to Inogen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inogen Inc. (INGN) Financial Data
Inogen Inc. has a market capitalization of $168.86M with a P/E ratio of -4.3x. The company generates $347.03M in trailing twelve-month revenue with a -7.3% profit margin.
Revenue growth is +4.0% quarter-over-quarter, while maintaining an operating margin of -7.0% and return on equity of -13.3%.
Valuation Metrics
Market Cap
$168.86M
Enterprise Value
$63.59M
P/E Ratio
-4.3x
PEG Ratio
0.2x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+4.0%
Gross Margin
+44.7%
Operating Margin
-7.0%
Net Margin
-7.3%
EPS Growth
+4.0%
Financial Health
Cash/Price Ratio
+69.8%
Current Ratio
3.1x
Debt/Equity
9.2x
ROE
-13.3%
ROA
-6.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inogen Inc. (INGN) Business Model
About Inogen Inc.
What They Do
Develops innovative respiratory products for patients.
Business Model
Inogen generates revenue by selling portable oxygen concentrators and related respiratory products to patients and healthcare providers. The company focuses on both direct sales and partnerships with distributors and resellers, allowing it to reach a wide range of customers in various healthcare settings.
Additional Information
Founded in 2001 and headquartered in Goleta, California, Inogen is committed to research and development, enhancing its product offerings and maintaining its position as a leader in the healthcare technology sector, particularly in portable oxygen solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
766
CEO
Mr. Kevin R. M. Smith
Country
United States
IPO Year
2014
Website
www.inogen.comInogen Inc. (INGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite
Inogen launches Aurora CPAP masks to expand its respiratory care suite and enter the growing sleep apnea market.
Jan 08, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Inogen will announce its Q4 and full-year 2025 financial results on February 24, 2026.
Why It Matters
Inogen's upcoming financial results announcement may impact its stock price and investor sentiment, indicating company performance and future growth potential.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Inogen has introduced Aurora CPAP masks to enhance its respiratory care offerings and tap into the expanding sleep apnea market.
Why It Matters
Inogen's launch of Aurora CPAP masks signals expansion into the lucrative sleep apnea market, potentially boosting revenue and market share, impacting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Positive
Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States
8 days ago
Quick Summary
Inogen has launched Aurora CPAP masks for obstructive sleep apnea in the U.S., expanding its product offerings in the airway clearance market.
Why It Matters
Inogen's launch of Aurora CPAP Masks expands its product line in the sleep apnea market, potentially increasing revenue and market share, which can positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
INGN reports strong Q3 sales driven by increased POC demand and new product launches, though competition and forex fluctuations may impact near-term growth.
Why It Matters
INGN's momentum from rising demand and strong sales indicates potential for growth, but competition and forex risks may impact short-term performance, influencing investor sentiment and strategy.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
AVAH, INGN, and CCLD are leveraging home care, portable oxygen technology, and cloud healthcare IT to enhance care delivery and efficiency through 2026.
Why It Matters
Home care, portable oxygen tech, and cloud healthcare IT innovations signal growth potential in healthcare sectors, influencing investment strategies and market positioning through 2026.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Inogen (INGN) is currently in oversold territory, suggesting potential for trend reversal, supported by Wall Street analysts raising earnings estimates.
Why It Matters
Inogen's oversold status and analysts' upgraded earnings estimates suggest potential for a price rebound, signaling a favorable entry point for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About INGN Stock
What is Inogen Inc.'s (INGN) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Inogen Inc. (INGN) has a median price target of $13.00. The highest price target is $14.00 and the lowest is $12.00.
Is INGN stock a good investment in 2026?
According to current analyst ratings, INGN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INGN stock?
Wall Street analysts predict INGN stock could reach $13.00 in the next 12 months. This represents a 100.0% increase from the current price of $6.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inogen Inc.'s business model?
Inogen generates revenue by selling portable oxygen concentrators and related respiratory products to patients and healthcare providers. The company focuses on both direct sales and partnerships with distributors and resellers, allowing it to reach a wide range of customers in various healthcare settings.
What is the highest forecasted price for INGN Inogen Inc.?
The highest price target for INGN is $14.00 from Anderson Schock at B. Riley Securities, which represents a 115.4% increase from the current price of $6.50.
What is the lowest forecasted price for INGN Inogen Inc.?
The lowest price target for INGN is $12.00 from Mike Matson at Needham, which represents a 84.6% increase from the current price of $6.50.
What is the overall INGN consensus from analysts for Inogen Inc.?
The overall analyst consensus for INGN is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are INGN stock price projections?
Stock price projections, including those for Inogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:14 AM UTC